Pharmaceutical access, cost and transparency
Primary
Senate, December 27, 2024 -- Report of the committee of conference on the disagreeing votes of the two branches with reference to the House amendment to the Senate relative to pharmaceutical access, costs and transparency (Senate, No. 2520) (amended by the House all after the enacting clause and inserting in place thereof the text of House document numbered 4910; and by striking out the title and inserting in place thereof the following title: “An Act promoting access and affordability of prescription drugs.”),-- reports, a “Bill relative to pharmaceutical access, costs and transparency” (Senate, No. 3012).
No votes to display
Enacted and laid before the Governor
Reported on S2520
Rules suspended
Committee of conference report accepted
Referred to the committee on House Steering, Policy and Scheduling
Committee reported that the matter be placed in the Orders of the Day for the next sitting, the question being on acceptance
Rules suspended
Committee of conference report accepted, in concurrence
Motion to reconsider negatived
Enacted
Motion to reconsider negatived
Reported from a committee of conference
| Bill Text Versions | Format |
|---|---|
| Bill Text |
| Document | Format |
|---|---|
| No related documents. |
Data on Open States is updated periodically throughout the day from the official website of the Massachusetts General Court.
If you notice any inconsistencies with these official sources, feel free to file an issue.
